KR100885325B1 - 변형된 모빌리바이러스 ｖ 단백질 - Google Patents

변형된 모빌리바이러스 ｖ 단백질 Download PDF

Info

Publication number
KR100885325B1
KR100885325B1 KR1020027017494A KR20027017494A KR100885325B1 KR 100885325 B1 KR100885325 B1 KR 100885325B1 KR 1020027017494 A KR1020027017494 A KR 1020027017494A KR 20027017494 A KR20027017494 A KR 20027017494A KR 100885325 B1 KR100885325 B1 KR 100885325B1
Authority
KR
South Korea
Prior art keywords
protein
virus
delete delete
mutations
mutation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020027017494A
Other languages
English (en)
Korean (ko)
Other versions
KR20030032971A (ko
Inventor
파크스크리스토퍼엘.
Original Assignee
와이어쓰 홀딩스 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 와이어쓰 홀딩스 코포레이션 filed Critical 와이어쓰 홀딩스 코포레이션
Publication of KR20030032971A publication Critical patent/KR20030032971A/ko
Application granted granted Critical
Publication of KR100885325B1 publication Critical patent/KR100885325B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18461—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
KR1020027017494A 2000-06-23 2001-06-21 변형된 모빌리바이러스 ｖ 단백질 Expired - Fee Related KR100885325B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21365500P 2000-06-23 2000-06-23
US60/213,655 2000-06-23

Publications (2)

Publication Number Publication Date
KR20030032971A KR20030032971A (ko) 2003-04-26
KR100885325B1 true KR100885325B1 (ko) 2009-02-25

Family

ID=22795965

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027017494A Expired - Fee Related KR100885325B1 (ko) 2000-06-23 2001-06-21 변형된 모빌리바이러스 ｖ 단백질

Country Status (17)

Country Link
US (1) US6664066B2 (https=)
EP (1) EP1292615B1 (https=)
JP (1) JP2004513616A (https=)
KR (1) KR100885325B1 (https=)
CN (1) CN1298738C (https=)
AT (1) ATE343589T1 (https=)
AU (2) AU2001267014B2 (https=)
BR (1) BR0111827A (https=)
CA (1) CA2409432C (https=)
CY (1) CY1105842T1 (https=)
DE (1) DE60124098T2 (https=)
DK (1) DK1292615T3 (https=)
ES (1) ES2273852T3 (https=)
IL (1) IL153004A0 (https=)
MX (1) MXPA02012256A (https=)
PT (1) PT1292615E (https=)
WO (1) WO2002000694A2 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2340499T3 (es) 2001-06-05 2010-06-04 Curevac Gmbh Arnm de antigeno tumoral estabilizado con un contenido de g/c aumentado.
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
DE10229872A1 (de) * 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
EP1633860A2 (en) 2003-06-09 2006-03-15 Wyeth IMPROVED METHOD FOR THE RECOVERY OF NON-SEGMENTED, NEGATIVE-STRANDED RNA VIRUSES FROM cDNA
DE102004042546A1 (de) * 2004-09-02 2006-03-09 Curevac Gmbh Kombinationstherapie zur Immunstimulation
EP2046954A2 (en) 2006-07-31 2009-04-15 Curevac GmbH NUCLEIC ACID OF FORMULA (I): GIXmGn, OR (II): CIXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT
US20090017517A1 (en) * 2007-07-13 2009-01-15 Medimmune, Llc Preparation of Negative-Stranded RNA Viruses by Electroporation
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
DK2176408T5 (en) 2008-01-31 2015-12-14 Curevac Gmbh Nucleic acids comprising FORMULA (NuGiXmGnNv) a AND DERIVATIVES AS IMMUNE STIMULATING AGENTS / ADJUVANTS.
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
KR101761388B1 (ko) 2010-07-30 2017-07-25 큐어백 아게 트랜스펙션 및 면역 자극을 위한 이황화-크로스링크된 양이온 성분 및 핵산의 복합체
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2625189B1 (en) 2010-10-01 2018-06-27 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE19216461T1 (de) 2011-10-03 2021-10-07 Modernatx, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
WO2013107290A1 (en) * 2012-01-20 2013-07-25 The Government of the Hong Kong Special Administrative Region of the People's Republic of China A novel paramyxovirus and uses thereof
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
BR112016003361A2 (pt) 2013-08-21 2017-11-21 Curevac Ag vacina do vírus sincicial respiratório (rsv)
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
WO2015062738A1 (en) 2013-11-01 2015-05-07 Curevac Gmbh Modified rna with decreased immunostimulatory properties
US10369216B2 (en) 2014-04-01 2019-08-06 Curevac Ag Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
US11100434B2 (en) 2014-05-06 2021-08-24 Uber Technologies, Inc. Real-time carpooling coordinating system and methods
US9552559B2 (en) 2014-05-06 2017-01-24 Elwha Llc System and methods for verifying that one or more directives that direct transport of a second end user does not conflict with one or more obligations to transport a first end user
US10458801B2 (en) 2014-05-06 2019-10-29 Uber Technologies, Inc. Systems and methods for travel planning that calls for at least one transportation vehicle unit
CN106537444A (zh) 2014-05-06 2017-03-22 埃尔瓦有限公司 用于要求至少一个运输车辆单元的出行计划的系统和方法
CA2955124C (en) * 2014-07-18 2024-01-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Peptides including a binding domain of the viral phosphoprotein (p) subunit to the viral rna free nucleoprotein (n0)
WO2016029168A1 (en) 2014-08-21 2016-02-25 Uber Technologies, Inc. Arranging a transport service for a user based on the estimated time of arrival of the user
US10685416B2 (en) 2015-12-10 2020-06-16 Uber Technologies, Inc. Suggested pickup location for ride services
US10731998B2 (en) 2017-11-05 2020-08-04 Uber Technologies, Inc. Network computer system to arrange pooled transport services

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE257175T1 (de) 1994-07-18 2004-01-15 Conzelmann Karl Klaus Prof Dr Rekombinantes infektiöses nicht-in-segmente- geteiltes, negativ-strange-rns-virus
ATE181112T1 (de) 1995-08-09 1999-06-15 Schweiz Serum & Impfinst Dem genom von minussträngigen rna-viren entsprechende cdna und verfahren zur herstellung von infektiösen minussträngigen rna-viren
CA2265554A1 (en) * 1996-09-27 1998-04-02 American Cyanamid Company 3' genomic promoter region and polymerase gene mutations responsible for attenuation in viruses of the order designated mononegavirales
BR9809456B1 (pt) 1997-05-23 2011-06-28 molécula isolada de polinucleotìdeo, composição de célula ou isenta de célula, partìcula de piv infeciosa, atenuada e imunogênica, e, composição imunogênica.
CA2323927A1 (en) * 1998-03-26 1999-09-30 American Cyanamid Company Mutations responsible for attenuation in measles virus or human respiratory syncytial virus subgroup b

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Journal of Virology, vol.72(10), pp. 7754-7761.
Virology, vol.267(1), pp.80-89.

Also Published As

Publication number Publication date
AU2001267014B2 (en) 2007-03-15
CN1298738C (zh) 2007-02-07
WO2002000694A3 (en) 2002-10-10
AU6701401A (en) 2002-01-08
CN1437613A (zh) 2003-08-20
CA2409432C (en) 2010-08-03
US20030206925A1 (en) 2003-11-06
DK1292615T3 (da) 2007-02-19
EP1292615B1 (en) 2006-10-25
EP1292615A2 (en) 2003-03-19
CY1105842T1 (el) 2011-02-02
PT1292615E (pt) 2007-01-31
DE60124098D1 (de) 2006-12-07
BR0111827A (pt) 2003-05-20
IL153004A0 (en) 2003-06-24
KR20030032971A (ko) 2003-04-26
JP2004513616A (ja) 2004-05-13
WO2002000694A2 (en) 2002-01-03
ATE343589T1 (de) 2006-11-15
CA2409432A1 (en) 2002-01-03
ES2273852T3 (es) 2007-05-16
DE60124098T2 (de) 2007-04-05
MXPA02012256A (es) 2003-04-25
US6664066B2 (en) 2003-12-16

Similar Documents

Publication Publication Date Title
KR100885325B1 (ko) 변형된 모빌리바이러스 ｖ 단백질
JP4237268B2 (ja) クローン化されたヌクレオチド配列からの弱毒化パラインフルエンザウィルスワクチンの製造
AU2001267014A1 (en) Modified morbillivirus V proteins
KR101020532B1 (ko) ｃＤＮＡ로부터의 비분절 네가티브 쇄 ＲＮＡ 바이러스의 회수를 위한 개선된 방법
US20070253972A1 (en) Rescue of mumps virus from cDNA
JP2000517194A (ja) モノネガビラレス（Ｍｏｎｏｎｅｇａｖｉｒａｌｅｓ）と称される目のウイルスにおける弱毒化の原因となる３’ゲノムプロモーター領域およびポリメラーゼ遺伝子の突然変異
AU2009202359A1 (en) Recovery of recombinant human parainfluenza virus type 1 (HPIV1) from cDNA use of recombinant HPIV1 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens
US7208161B1 (en) Production of attenuated parainfluenza virus vaccines from cloned nucleotide sequences
WO2002000883A2 (en) Rescue of canine distemper virus from cdna
KR20180085730A (ko) 키메라 rsv, 면역원성 조성물, 및 사용 방법
JP2003504064A (ja) 弱毒ヒト−ウシキメラ−パラインフルエンザウイルス（ｐｉｖ）ワクチン
EP1480671B1 (en) Recombinant rsv virus expression systems and vaccines
US20120308602A1 (en) Recombinant RSV Virus Expression Systems And Vaccines
Skiadopoulos et al. Attenuation of the recombinant human parainfluenza virus type 3 cp45 candidate vaccine virus is augmented by importation of the respiratory syncytial virus cpts530 L polymerase mutation
US7201907B1 (en) Attenuated human-bovine chimeric parainfluenza virus(PIV) vaccines
EP1877548B1 (en) Attenuated human parainfluenza virus, methods and uses thereof
JP2002507408A (ja) 麻疹ウイルスもしくはヒト呼吸合胞体ウイルスサブグループｂの弱毒化の原因である突然変異
US7361496B1 (en) Rescue of mumps virus from cDNA
AU2005237174A1 (en) Rescue of mumps virus from CDNA
AU2004237877A1 (en) 3' genomic promoter region and polymerase gene mutations responsible for attenuation in viruses of the order designated mononegavirales

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PE0801 Dismissal of amendment

St.27 status event code: A-2-2-P10-P12-nap-PE0801

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20120218

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20120218

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000